Welcome to our dedicated page for OS THERAPIES INCORPORATED SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OS Therapies Incorporated (OSTX) SEC filings page on Stock Titan brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a primary source view of its clinical-stage oncology business. As a NYSE American–listed emerging growth company, OS Therapies uses current reports on Form 8-K, registration statements, and proxy materials to describe its listeria-based cancer immunotherapy programs, ADC and drug conjugate platform, capital structure, and governance decisions.
Investors can use this page to access Form 8-K filings that detail material events such as warrant exercise inducement and exchange offers, gross proceeds from warrant exercises, and the terms of new warrants issued to accredited investors. These filings explain how OS Therapies raises capital to support regulatory submissions and commercial preparation for its lead asset OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and to fund preparations for the proposed spin-off of its veterinary subsidiary, OS Animal Health.
Other 8-Ks and the company’s definitive proxy statement on Schedule 14A provide insight into corporate governance, including amendments to the certificate of incorporation to increase authorized common stock, changes to the 2023 Incentive Compensation Plan, quorum requirements under the bylaws, and shareholder approvals related to potential share issuances and a shareholder rights agreement. Registration statements on Form S-1 and Form S-3 describe the resale of shares underlying warrants, the company’s status as a smaller reporting company and emerging growth company, and the use of proceeds from warrant exercises.
Through Stock Titan, these filings are updated in near real time from EDGAR and are paired with AI-powered summaries that translate legal and financial language into plain English. Users can quickly understand the key points of complex documents, such as how a warrant inducement affects dilution, what changes a bylaw amendment introduces, or how a registration statement relates to existing warrants. Over time, this filings archive helps investors follow OS Therapies’ progress as it advances OST-HER2 through the regulatory process, develops its tunable ADC (tADC) platform, and executes on planned transactions like the OS Animal Health spin-off.
OS Therapies Incorporated (NYSE American: OSTX) filed an 8-K to disclose a warrant-exercise inducement designed to raise up to $8 million in gross cash proceeds. The company has entered into Inducement Offer Letters with holders of 1,574,288 outstanding common-stock warrants that currently carry a $1.12 exercise price. In exchange for the holders exercising these warrants for cash during the June 20–July 10, 2025 �Inducement Period,� OSTX will issue an equal number of New Warrants priced at $3.00 per share and exercisable immediately for five years.
The company has retained an SEC-registered, FINRA-member broker as exclusive solicitation agent; it will receive a 5.0 % cash fee on total proceeds plus reimbursement of up to $15,000 in expenses. Assuming full participation, OSTX expects to receive roughly $8 million in gross proceeds before fees and expenses.
Use of proceeds: management plans to fund U.S. and international regulatory and pre-commercial activities aimed at securing marketing authorisations for OST-HER2 in preventing or delaying recurrent, fully resected, lung-metastatic osteosarcoma, and for general corporate purposes.
Key terms of the New Warrants:
- Exercise price: $3.00; immediately exercisable; five-year term.
- Anti-dilution: price resets to the lower of any future equity issuance price or $1.00.
- Beneficial-ownership cap: 4.99 % (optionally 9.99 %) unless 61-day prior notice is given.
- Forced exercise allowed if OSTX trades ≥300 % of exercise price for 20 consecutive trading days, subject to equity conditions.
- Cashless exercise permitted if resale registration is unavailable.
- Fundamental-transaction protection via Black-Scholes cash-out or assumption by successor.
Registration: Existing Warrant shares are already covered by effective S-1 registrations (333-284631 & 333-287569). OSTX will file a resale registration statement for the New Warrant shares within 30 days of the final closing and seek SEC effectiveness within 60–90 days thereafter.
The securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, constituting an unregistered private placement.